Passion and purpose to transform patient journeys in anxiety and depression.

Jon S. Saxe, J.D., LL.M., served as Chair of our Board of Directors from 2000 until October 2023 and currently serves as Chair of our Audit Committee. Mr. Saxe is the retired President and was a director of PDL BioPharma (operations acquired by Abbott) from 1989 to 2008. From 1989 to 1993, he was President, Chief Executive Officer, and a director of Synergen (acquired by Amgen). Mr. Saxe served as Vice President, Licensing & Corporate Development for Hoffmann-Roche Inc. from 1984 through 1989, and Head of Patent Law for Hoffmann-Roche from 1978 through 1989. Mr. Saxe currently is the lead director of K2X Technology and Life Science, an investment fund, and is a director of six private life science companies: Achelios Therapeutics, Arbor Vita Corporation, Aether, Inc., NuvOx Pharma, Trellis Bioscience, Inc., and Epalex Corporation. Mr. Saxe has also served as a director of other biotechnology and pharmaceutical companies, including ID Biomedical (acquired by GlaxoSmithKline), Sciele Pharmaceuticals, Inc. (acquired by Shionogi), Amalyte (acquired by Kemin Industries), Cell Pathways (acquired by OSI Pharmaceuticals), Lumos Pharma, Inc. (merged with New Link Genetics), and other companies, both public and private. Mr. Saxe has a B.S.Ch.E. from Carnegie-Mellon University, a J.D. degree from George Washington University, and an LL.M. degree from New York University.University.